Introduction
============

The use of oral anticancer agents has increased in modern oncology treatment: 25% of cancer chemotherapy currently in development can be taken orally.[@b1-ppa-9-561] The use of oral anticancer drugs improves the quality of life of cancer patients by reducing hospital stay and giving them a greater sense of control over their treatment,[@b2-ppa-9-561] but it poses important challenges such as managing side effects, prolonged treatment period, and adherence issues.

Patient adherence is defined as the number of doses taken as a percentage of the number expected. Adherence to prescribed treatment regimens for chronic nononcologic diseases averages \<80%.[@b3-ppa-9-561],[@b4-ppa-9-561] Patients with cancer, because it is a life-threatening disease, are expected to be particularly adherent to medication.[@b5-ppa-9-561]--[@b7-ppa-9-561] Several studies have been published investigating patient adherence to capecitabine; median adherence across all cycles and studies was 78%.[@b8-ppa-9-561],[@b9-ppa-9-561] Winterhalder et al[@b5-ppa-9-561] used participant self-reports to explore adherence in patients with gastrointestinal and breast cancer.

Patients in the present study were treated with the chemotherapeutic agent capecitabine (Xeloda; Hoffmann-La Roche Ltd., Basel, Switzerland), a fluoropyrimidine that is an orally administered prodrug of cytotoxic fluorouracil (5-FU). Capecitabine, which is frequently used in the treatment of colorectal or gastric cancer, has improved tolerability and comparable efficacy compared with infusional or bolus 5-FU[@b10-ppa-9-561] and has similar efficacy to bolus 5-FU/folinic acid in the first-line treatment of metastatic colorectal cancer.[@b11-ppa-9-561]--[@b13-ppa-9-561] XELOX, a regimen combining capecitabine and oxaliplatin, consists of the standard 21-day intermittent schedule (ie, 14 days on followed by 7 days off) of capecitabine combined with oxaliplatin on day 1.

Adherence is crucial for the success of oral anticancer agent therapy. However, many oncologists, pharmacists, and nurses do not check for oral anticancer agent adherence in ambulatory practice, even though understanding the reasons for nonadherence is essential for the development of interventions to improve adherence. In this study, adherence to capecitabine during XELOX treatment was checked by pharmacists via a patient-reported treatment diary at our pharmaceutical outpatient clinic for metastatic colorectal cancer. The aim of the study was to evaluate real-life adherence via retrospective cohort analysis of Japanese patients undergoing XELOX treatment.

Materials and methods
=====================

Study design
------------

Enrollment criteria comprised patients who received XELOX treatment for metastatic colorectal cancer between October 1, 2009 and March 31, 2012 at the Cancer Institute Hospital, Japanese Foundation for Cancer Research and who attended a pharmaceutical outpatient clinic. We included 242 consecutive patients. Adherence to capecitabine was checked by pharmacists with a patient-reported treatment diary at the pharmaceutical outpatient clinic. Adherence rate was defined as the number of times that a patient took capecitabine in a 14-day cycle/28 doses prescribed. The Clinical Research Ethics Review Committee of the Japanese Foundation for Cancer Research, Cancer Institute Hospital approved this research (approval no: 2012-1035).

Data collection
---------------

Adherence to capecitabine was checked by pharmacists via a patient-reported treatment diary. The reasons for nonadherence were established by these pharmacists. We retrospectively surveyed median relative dose intensities[@b14-ppa-9-561] of capecitabine and the factors deteriorating compliance over eight treatment cycles using electronic patient records. Differences in compliance rates were examined according to patient age and tested using the chi-square test.

The Bonferroni correction was used to conservatively account for multiple comparisons. All *P*-values reported were two-sided, and a level of 0.05 was considered statistically significant. Statistical analyses were performed using SPSS, version 11.5.

Results
=======

Patient characteristics
-----------------------

The study included 144 male and 98 female patients ([Table 1](#t1-ppa-9-561){ref-type="table"}). Their mean age was 63 years (range 27--86). All patients were diagnosed with metastatic colorectal cancer and most (92.9%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0; 17 patients (7.1%) had an ECOG performance status of 1. Capecitabine was prescribed as XELOX + bevacizumab treatment for 162 (66.9%) participants while 80 (33.1%) received XELOX treatment. The median relative dose intensity of capecitabine was 79.2%.

Self-reported adherence
-----------------------

Overall, 124 patients (51.2%) did not record any intake mistakes with capecitabine therapy and were considered fully compliant while 118 patients (48.8%, 1,561 instances) reported some kind of compliance error. The rate of overadherence was 1.5% (n=23). Median adherence rates were 93.5% (n=242) in the first cycle of XELOX treatment and 95.5% (n=229) in the second cycle, rising to 96.1% (n=148) in the eighth cycle ([Figure 1](#f1-ppa-9-561){ref-type="fig"}). The reasons for nonadherence were diarrhea (22.5%, 352 instances), nausea/vomiting (13.8%, 215 instances), fever (12.7%, 198 instances), missed dose (12.1%, 189 instances), ileus/constipation (6.5%, 102 instances), and progressive disease (5.6%, 87 instances) ([Figure 2](#f2-ppa-9-561){ref-type="fig"}). The medications most commonly used were skin moisturizer (100%) and antidiarrheal (one-time-only dose) (100%).

The rate of missed dose was 12.1%. We categorized the patients who missed a dose of capecitabine according to the number of times it occurred: ≥10 times, three patients (1.2%); 6≤9 times, seven patients (2.9%); 3≤5 times, nine patients (3.7%); once or twice, 31 patients (12.8%) in eight cycles of XELOX treatment ([Figure 3](#f3-ppa-9-561){ref-type="fig"}).

Relationship of self-reported adherence and age
-----------------------------------------------

The reported rate of adherence to capecitabine in the first treatment cycle was 80.4% in patients aged ≥80 years, 94.0% in the 70--80 years group, and 93.8% for patients aged \<70 years ([Figure 4](#f4-ppa-9-561){ref-type="fig"}). Median relative dose intensities of capecitabine were 57.3% in the group of patients aged ≥80 years, 77.0% in the 70--80 years group, and 82.0% in patients aged \<70 years. An analysis of the probability of adherence issues in relation to patient age revealed a trend toward better adherence with capecitabine therapy in younger patients (hazard ratio =3.83; 95% confidence interval 2.48--5.91, *P*\<0.001 versus 70--80 years group and versus \<70 years group; chi-square test).

Discussion
==========

This research identified the adherence rate to capecitabine, and the factors that decrease it, at a pharmaceutical outpatient clinic over eight treatment cycles. Especially, overadherence was 1.5% and 12.1% of doses were missed; 4.1% of patients made five or more errors. Adherence was statistically significantly lower in patients aged ≥80 years compared with younger patients. (*P*\<0.001 versus 70--80 years group and versus \<70 years group; chi-square test).

Cancer patients are generally expected to have higher adherence to treatment than other patients because they are highly motivated by the gravity of their disease.[@b15-ppa-9-561],[@b16-ppa-9-561] However, studies have shown cancer patients to have similar adherence rates to patients with other diseases.[@b17-ppa-9-561]--[@b19-ppa-9-561] Treatment duration plays a role in adherence to the regimen: when medication is continued over a longer period of time, patients become less adherent.[@b20-ppa-9-561] Most of the studies included heterogeneous target tumor types, regimens, and therapy settings.[@b21-ppa-9-561] Our study focused on metastatic colorectal cancer and on XELOX treatment in clinical practice. We have explored the problem of medication adherence in cancer patients; our data in a limited tumor type and regimen will be highly useful and valuable.

One of the major limitations to medication event monitoring systems is that they are feasible in only some health care systems. Also, they are not suitable for oral cytotoxic agents, which require close monitoring of side effects and regular patient visits. There is no gold-standard measurement, and all methods have limitations.[@b17-ppa-9-561],[@b22-ppa-9-561] Previous studies of oral cytotoxic chemotherapeutic drugs have mainly used self-reported questionnaires,[@b23-ppa-9-561] which tend to overestimate adherence because patients are inclined to over-report to please their doctors. It seems likely that patient-completed diaries may be less influenced by this issue, because the patient is asked to record each dose as it is taken. Therefore, we used self-reported adherence based on many patient-completed medication diaries.

Associated factors influencing nonadherence to oral anticancer drugs are multifactorial and interrelated.[@b24-ppa-9-561],[@b25-ppa-9-561] Treatment-related side effects are the most frequently reported therapy-related factors associated with nonadherence to capecitabine,[@b5-ppa-9-561] and age is another predominant factor.[@b21-ppa-9-561] Our study indicated that nonadherence was correlated with increasing number of adverse effects. The most common side effects of capecitabine are gastrointestinal disorders (diarrhea, nausea, vomiting) and hand--foot syndrome. We prescribed supportive therapy for all cases in this study beforehand, but it is thought that patients do not always use supportive treatments appropriately. Thus, it is necessary to provide patient-tailored educational support[@b26-ppa-9-561],[@b27-ppa-9-561] and management of symptoms during follow-up.[@b28-ppa-9-561]

The rate of missed dose was 12.1%, and approximately 5% of patients habitually missed medicine. A main factor causing patients to miss a dose is eating out. However, in our study, it became apparent that more than 95% of patients had good adherence to capecitabine. Many studies provide limited information regarding the relationship between nonadherence and severity of side effects. Our data identified how often the capecitabine missed dose occurred in association with XELOX treatment in first-line treatment for metastatic colorectal cancer.

The adherence of the approximately 5% of patients who are intentionally nonadherent could be enhanced by means of advanced educational pharmaceutical care interventions. Behavioral interventions such as medication dosette boxes or alarm clocks and education about the characteristics of the drug capecitabine, possible adverse events, and their appropriate management, as well as the individual treatment regimen in detail, could be used more extensively to improve adherence in unintentionally nonadherent patients.

Self-reported compliance with capecitabine in patients with gastrointestinal and breast cancer was not influenced by age.[@b5-ppa-9-561] However, in this study, patients aged ≥80 years exhibited significantly decreased adherence compared with younger patients. Additionally, median relative dose intensities of capecitabine were not shown in previous studies;[@b5-ppa-9-561] we found median relative dose intensities of capecitabine of 57.3% in the ≥80 years group, 77.0% in the 70--80 years group, and 82.0% in the \<70 years group. We consider the findings from this study to be an important part of understanding lower relative dose intensity and adherence with capecitabine in patients aged ≥80 years.

Younger[@b20-ppa-9-561],[@b29-ppa-9-561],[@b30-ppa-9-561] and older age[@b19-ppa-9-561],[@b20-ppa-9-561],[@b31-ppa-9-561] have both been reported to be associated with nonadherence in patients taking oral anticancer drugs. Younger age was defined as ≤45 years,[@b20-ppa-9-561],[@b29-ppa-9-561] older as ≥85 years.[@b20-ppa-9-561] Older age was also found to be associated with lower persistence with the oral anticancer drug treatment. In this study, patients aged ≥80 years exhibited significantly lower compliance compared with younger patients. Patient eligibility in a previous randomized Phase III study of XELOX as first-line therapy for metastatic colorectal cancer was ≥18 years, with the oldest enrolled patient aged 86 years.[@b30-ppa-9-561] Those aged ≥80 years had lower compliance with capecitabine than younger participants; nevertheless, the median relative dose intensity of capecitabine in the ≥80 years group was 57.3% in our study. In the case of patients aged ≥80 years, a switch to injection therapy, FOLFOX, might be considered in some cases. It became clear in our study that adherence in younger patients was high (90%). A major limitation of our study is the relatively small number of patients aged \>80 years. Further research should include more elderly patients.

Checking adherence to oral anticancer drugs via pharmaceutical outpatient clinics is of considerable clinical importance. Pharmacist interventions can significantly improve medication adherence.[@b32-ppa-9-561] An oral chemotherapy management clinic service by a pharmacist was effective in delivering early interventions, resulting in decreased rates of adverse effects, nonadherence, drug interactions, and medication errors over time.[@b33-ppa-9-561] The identification of potential predictors of adherence would facilitate the utilization and broad application of the proposed adherence screening and modular medication management. The results of this study, obtained from a pharmaceutical outpatient clinic, demonstrate the adherence rate and the factors deteriorating the compliance with capecitabine over eight treatment cycles. Patients aged 80 years and over were suggested to be statistically significantly at risk of nonadherence to capecitabine with XELOX treatment. Our data provide important information about optimizing patients' care.
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![Capecitabine adherence rate on XELOX treatment.\
**Notes:** Adherence rate with capecitabine during cycles 1--8; Adherence to capecitabine was checked by pharmacists via the patients' self-reported treatment diaries at a pharmaceutical outpatient clinic; The reason for the number of patients decreasing through the cycles is deviation from XELOX therapy.\
**Abbreviation:** XELOX, capecitabine plus oxaliplatin.](ppa-9-561Fig1){#f1-ppa-9-561}

![Factors reducing adherence to capecitabine on XELOX treatment (n=1,561).\
**Note:** Factors reducing adherence to capecitabine during cycles 1--8.\
**Abbreviation:** XELOX, capecitabine plus oxaliplatin.](ppa-9-561Fig2){#f2-ppa-9-561}
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![Effect of age on adherence to capecitabine.\
**Notes:** Adherence to capecitabine in the first cycle, by patient age. In the ≥80 years group (n=6), there were 135 doses of capecitabine taken (168 recommended); 1,474 doses were taken (1,568 recommended) in the 70--80 years group (n=56); 4,725 doses were taken (5,040 recommended) in the \<70 years group (n=180); \**P*\<0.001 compared with the 70--80 years group; \*\**P*\<0.001 compared with the \<70 years group.](ppa-9-561Fig4){#f4-ppa-9-561}

###### 

Baseline patient characteristics

  Characteristics           Patients (n=242)   \%
  ------------------------- ------------------ ------
  Sex                                          
   Male                     144                59.5
   Female                   98                 40.5
  Age, years                                   
   Median                   63                 
   Range                    27--86             
  ECOG performance status                      
   0                        225                92.9
   1                        17                 7.1
   2                        0                  0
  Primary tumor site                           
   Colonic                  128                52.9
   Rectal                   88                 36.3
   Cecal                    15                 6.2
   Appendiceal              11                 4.5
  Chemotherapy                                 
   XELOX + bevacizumab      162                66.9
   XELOX                    80                 33.1

**Abbreviations:** ECOG, Eastern Cooperative Oncology Group; XELOX, capecitabine plus oxaliplatin.
